Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Feb;79(5-6):754–758. doi: 10.1038/sj.bjc.6690121

Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas

D Freihoff 1, A Kempe 1, B Beste 1, B Wappenschmidt 1, E Kreyer 1, Y Hayashi 2, A Meindl 3, D Krebs 1, O D Wiestler 1, A von Deimling 2, R K Schmutzler 1,2
PMCID: PMC2362671  PMID: 10070865

Abstract

PTEN is a novel tumour-suppressor gene located on chromosomal band 10q23.3. This region displays frequent loss of heterozygosity (LOH) in a variety of human neoplasms including breast carcinomas. The detection of PTEN mutations in Cowden disease and in breast carcinoma cell lines suggests that PTEN may be involved in mammary carcinogenesis. We here report a mutational analysis of tumour specimens from 103 primary breast carcinomas and constitutive DNA from 25 breast cancer families. The entire coding region of PTEN was screened by single-strand conformation polymorphism (SSCP) analysis and direct sequencing using intron-based primers. No germline mutations could be identified in the breast cancer families and only one sporadic carcinoma carried a PTEN mutation at one allele. In addition, all sporadic tumours were analysed for homozygous deletions by differential polymerase chain reaction (PCR) and for allelic loss using the microsatellite markers D10S215, D10S564 and D10S573. No homozygous deletions were detected and only 10 out of 94 informative tumours showed allelic loss in the PTEN region. These results suggest that PTEN does not play a major role in breast cancer formation. 1999 Cancer Research Campaign

Keywords: PTEN/MMAC1/TEP1, breast cancer, mutations, LOH10q, tumour-suppressor gene

Full Text

The Full Text of this article is available as a PDF (107.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bender B., Wiestler O. D., von Deimling A. A device for processing large acrylamide gels. Biotechniques. 1994 Feb;16(2):204–206. [PubMed] [Google Scholar]
  3. Bocker T., Diermann J., Friedl W., Gebert J., Holinski-Feder E., Karner-Hanusch J., von Knebel-Doeberitz M., Koelble K., Moeslein G., Schackert H. K. Microsatellite instability analysis: a multicenter study for reliability and quality control. Cancer Res. 1997 Nov 1;57(21):4739–4743. [PubMed] [Google Scholar]
  4. Boström J., Cobbers J. M., Wolter M., Tabatabai G., Weber R. G., Lichter P., Collins V. P., Reifenberger G. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res. 1998 Jan 1;58(1):29–33. [PubMed] [Google Scholar]
  5. Chen J., Lindblom P., Lindblom A. A study of the PTEN/MMAC1 gene in 136 breast cancer families. Hum Genet. 1998 Jan;102(1):124–125. [PubMed] [Google Scholar]
  6. Dahia P. L., FitzGerald M. G., Zhang X., Marsh D. J., Zheng Z., Pietsch T., von Deimling A., Haluska F. G., Haber D. A., Eng C. A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene. 1998 May 7;16(18):2403–2406. doi: 10.1038/sj.onc.1201762. [DOI] [PubMed] [Google Scholar]
  7. Duerr E. M., Rollbrocker B., Hayashi Y., Peters N., Meyer-Puttlitz B., Louis D. N., Schramm J., Wiestler O. D., Parsons R., Eng C. PTEN mutations in gliomas and glioneuronal tumors. Oncogene. 1998 Apr 30;16(17):2259–2264. doi: 10.1038/sj.onc.1201756. [DOI] [PubMed] [Google Scholar]
  8. Fearon E. R. Human cancer syndromes: clues to the origin and nature of cancer. Science. 1997 Nov 7;278(5340):1043–1050. doi: 10.1126/science.278.5340.1043. [DOI] [PubMed] [Google Scholar]
  9. Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A. F., Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 1997 Sep 1;57(17):3660–3663. [PubMed] [Google Scholar]
  10. Hayashi Y., Ueki K., Waha A., Wiestler O. D., Louis D. N., von Deimling A. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol. 1997 Jul;7(3):871–875. doi: 10.1111/j.1750-3639.1997.tb00890.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kerangueven F., Eisinger F., Noguchi T., Allione F., Wargniez V., Eng C., Padberg G., Theillet C., Jacquemier J., Longy M. Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions. Oncogene. 1997 Jan 23;14(3):339–347. doi: 10.1038/sj.onc.1200818. [DOI] [PubMed] [Google Scholar]
  12. Kong D., Suzuki A., Zou T. T., Sakurada A., Kemp L. W., Wakatsuki S., Yokoyama T., Yamakawa H., Furukawa T., Sato M. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet. 1997 Oct;17(2):143–144. doi: 10.1038/ng1097-143. [DOI] [PubMed] [Google Scholar]
  13. Lancaster J. M., Wooster R., Mangion J., Phelan C. M., Cochran C., Gumbs C., Seal S., Barfoot R., Collins N., Bignell G. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet. 1996 Jun;13(2):238–240. doi: 10.1038/ng0696-238. [DOI] [PubMed] [Google Scholar]
  14. Li D. M., Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 1997 Jun 1;57(11):2124–2129. [PubMed] [Google Scholar]
  15. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S. I., Puc J., Miliaresis C., Rodgers L., McCombie R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997 Mar 28;275(5308):1943–1947. doi: 10.1126/science.275.5308.1943. [DOI] [PubMed] [Google Scholar]
  16. Liaw D., Marsh D. J., Li J., Dahia P. L., Wang S. I., Zheng Z., Bose S., Call K. M., Tsou H. C., Peacocke M. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997 May;16(1):64–67. doi: 10.1038/ng0597-64. [DOI] [PubMed] [Google Scholar]
  17. Miki Y., Katagiri T., Kasumi F., Yoshimoto T., Nakamura Y. Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet. 1996 Jun;13(2):245–247. doi: 10.1038/ng0696-245. [DOI] [PubMed] [Google Scholar]
  18. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L. M., Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66–71. doi: 10.1126/science.7545954. [DOI] [PubMed] [Google Scholar]
  19. Nelen M. R., van Staveren W. C., Peeters E. A., Hassel M. B., Gorlin R. J., Hamm H., Lindboe C. F., Fryns J. P., Sijmons R. H., Woods D. G. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet. 1997 Aug;6(8):1383–1387. doi: 10.1093/hmg/6.8.1383. [DOI] [PubMed] [Google Scholar]
  20. Rasheed B. K., Stenzel T. T., McLendon R. E., Parsons R., Friedman A. H., Friedman H. S., Bigner D. D., Bigner S. H. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 1997 Oct 1;57(19):4187–4190. [PubMed] [Google Scholar]
  21. Remmele W., Hildebrand U., Hienz H. A., Klein P. J., Vierbuchen M., Behnken L. J., Heicke B., Scheidt E. Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch A Pathol Anat Histopathol. 1986;409(2):127–147. doi: 10.1007/BF00708323. [DOI] [PubMed] [Google Scholar]
  22. Rhei E., Kang L., Bogomolniy F., Federici M. G., Borgen P. I., Boyd J. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res. 1997 Sep 1;57(17):3657–3659. [PubMed] [Google Scholar]
  23. Schmutzler R. K., Bierhoff E., Werkhausen T., Fimmers R., Speiser P., Kubista E., Krebs D., Zeillinger R., Wiestler O. D., Von Deimling A. Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast carcinoma. Int J Cancer. 1997 Jun 20;74(3):322–325. doi: 10.1002/(sici)1097-0215(19970620)74:3<322::aid-ijc15>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  24. Singh B., Ittmann M. M., Krolewski J. J. Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosomes Cancer. 1998 Feb;21(2):166–171. [PubMed] [Google Scholar]
  25. Sourvinos G., Kiaris H., Tsikkinis A., Vassilaros S., Spandidos D. A. Microsatellite instability and loss of heterozygosity in primary breast tumours. Tumour Biol. 1997;18(3):157–166. doi: 10.1159/000218026. [DOI] [PubMed] [Google Scholar]
  26. Steck P. A., Pershouse M. A., Jasser S. A., Yung W. K., Lin H., Ligon A. H., Langford L. A., Baumgard M. L., Hattier T., Davis T. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997 Apr;15(4):356–362. doi: 10.1038/ng0497-356. [DOI] [PubMed] [Google Scholar]
  27. Tashiro H., Blazes M. S., Wu R., Cho K. R., Bose S., Wang S. I., Li J., Parsons R., Ellenson L. H. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997 Sep 15;57(18):3935–3940. [PubMed] [Google Scholar]
  28. Tsou H. C., Teng D. H., Ping X. L., Brancolini V., Davis T., Hu R., Xie X. X., Gruener A. C., Schrager C. A., Christiano A. M. The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. Am J Hum Genet. 1997 Nov;61(5):1036–1043. doi: 10.1086/301607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Ueda K., Nishijima M., Inui H., Watatani M., Yayoi E., Okamura J., Yasutomi M., Nakamura Y., Miyoshi Y. Infrequent mutations in the PTEN/MMAC1 gene among primary breast cancers. Jpn J Cancer Res. 1998 Jan;89(1):17–21. doi: 10.1111/j.1349-7006.1998.tb00473.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Wang S. I., Puc J., Li J., Bruce J. N., Cairns P., Sidransky D., Parsons R. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 1997 Oct 1;57(19):4183–4186. [PubMed] [Google Scholar]
  31. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995 Dec 21;378(6559):789–792. doi: 10.1038/378789a0. [DOI] [PubMed] [Google Scholar]
  32. von Deimling A., Bender B., Louis D. N., Wiestler O. D. A rapid and non-radioactive PCR based assay for the detection of allelic loss in human gliomas. Neuropathol Appl Neurobiol. 1993 Dec;19(6):524–529. doi: 10.1111/j.1365-2990.1993.tb00481.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES